

Table S2: Summary of quality assessment based on the Newcastle-Ottawa quality assessment scale for **cross-sectional studies on viral load and duration of detection** [1].

Study	Design	Study quality						Overall quality (sum)	Reference
		S1	S2	S4	C1	O1	O2		
Puhach 2022	Cross-sectional study	*	-	*	-	**	*	5	[2]
Luo 2022	Cross-sectional study	*	-	*	**	**	*	7	[3]
Ioannou 2021	Cross-sectional study	-	-	*	*	**	-	4	[4]
Bramante 2022	Cross-sectional study	*	-	-	**	**	*	7	[5]
Bollinger 2022	Cross-sectional study	*	*	*	*	**	*	7	[6]
Levine-Tiefenbrun 2021	Cross-sectional study	*	*	*	*	**	-	6	[7]
Brown 2021	Cross-sectional study (outbreak investigation)	*	-	*	-	**	-	4	[8]
Park 2022	Cross-sectional study (outbreak investigation)	-	-	*	-	**	-	3	[9]
Caserta 2022	Cross-sectional study	*	-	*	-	**	-	4	[10]
Plante 2022	Cross-sectional study	-	-	*	*	**	*	5	[11]
Acharya 2022	Cross-sectional study	*	-	*	*	**	*	6	[12]
Griffin 2021	Cross-sectional study	*	-	*	-	**	*	5	[13]
Riemersma 2022	Cross-sectional study	*	-	**	*	**	*	7	[14]

Altawalah 2021	Cross-sectional study	*	-	*	-	**	*	5	[15]
Li 2022	Cross-sectional study	-	-	*	-	**	*	4	[16]
Fall 2022	Cross-sectional study	-	-	*	*	**	*	5	[17]
Hsu 2021	Cross-sectional study	*	-	*	-	**	*	3	[18]
Servellita 2022	Cross-sectional study	*	-	*	-	**	*	5	[19]
Colavita 2022	Cross-sectional study	*	-	*	-	**	*	5	[20]
Miguera 2022	Cross-sectional study	*	-	*	*	**	*	6	[21]
Rife Magalis 2022	Cross-sectional study	*	-	-	-	**	*	4	[22]
Laura 2022	Cross-sectional study	-	-	*	**	**	*	6	[23]

Selection

S1: Representativeness of the sample (maximum: *)

S2: Sample size (maximum: *)

S4: Ascertainment of exposure (confirmation of vaccination) (maximum: **)

Comparability

C1: Comparability of groups on the basis of the design or analysis (**)

Time since beginning of symptoms: *; additional relevant clinical parameters like age, sex or comorbidities: *

Outcome

O1: Assessment of outcome (measurement of viral load; test protocol) (maximum: **)

O2: Statistical test (maximum: *)

Additional explanation: The modified Newcastle-Ottawa quality assessment scale typically includes an assessment of the non-respondents (selection, point 3). This quality parameter was considered to be of no relevance for the question of the review because viral load measurements were not dependent on the study participants response rate.

References

- [1] Moskalewicz A, Oremus M. No clear choice between Newcastle-Ottawa Scale and Appraisal Tool for Cross-Sectional Studies to assess methodological quality in cross-sectional studies of health-related quality of life and breast cancer. *J Clin Epidemiol* 2020; 120: 94–103. doi:10.1016/J.JCLINEPI.2019.12.013
- [2] Puhach O, Adea K, Hulo N, et al. Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. *Nat Med* 2022; 28: 1491–1500. doi:10.1038/s41591-022-01816-0
- [3] Luo CH, Morris CP, Sachithanandham J, et al. Infection With the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta Variant Is Associated With Higher Recovery of Infectious Virus Compared to the Alpha Variant in Both Unvaccinated and Vaccinated Individuals. *Clin Infect Dis* 2022; 75: e715–e725. doi:10.1093/CID/CIAB986
- [4] Ioannou P, Karakostas S, Astrinaki E, et al. Transmission of SARS-CoV-2 variant B.1.1.7 among vaccinated health care workers. *Infect Dis* 2021; 53: 876–879. doi:10.1080/23744235.2021.1945139
- [5] Bramante CT, Proper JL, Boulware DR, et al. Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic Symptoms. *Open Forum Infect Dis* 2022; 9: ofac066. doi:10.1093/OFID/OFAC066
- [6] Bollinger M, Saile P, Shapeton AD, et al. Sensitivity of severe acute respiratory syndrome coronavirus type 2 rapid antigen point-of-care tests in vaccinated patients. *Eur J Emerg Med* 2022; 29: 285–290. doi:10.1097/MEJ.0000000000000928
- [7] Levine-Tiefenbrun M, Yelin I, Alapi H, et al. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. *Nat Med* 2021; 27: 2108–2110. doi:10.1038/s41591-021-01575-4
- [8] Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021. *MMWR Morb Mortal Wkly Rep* 2021; 70: 1059–1062. doi:10.15585/mmwr.mm7031e2
- [9] Park SY, Kim TH, Lee E, et al. A SARS-CoV-2 outbreak associated with vaccine breakthrough in an acute care hospital. *Am J Infect Control* 2022; 50: 1006–1012. doi:10.1016/J.AJIC.2022.05.010
- [10] Caserta LC, Martins M, Cronk B, et al. Infection and Transmission of SARS-CoV-2 B.1.617.2 Lineage (Delta Variant) among Fully Vaccinated Individuals. *Microbiol Spectr* 2022; 10: e0056322. doi:10.1128/SPECTRUM.00563-22
- [11] Plante JA, Machado RRG, Mitchell BM, et al. Vaccination Decreases the Infectious Viral Load of Delta Variant SARS-CoV-2 in Asymptomatic Patients. *Viruses* 2022; 14: 2071. doi:10.3390/V14092071
- [12] Acharya CB, Schrom J, Mitchell AM, et al. Viral Load Among Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Persons Infected With the SARS-CoV-2 Delta Variant. *Open Forum Infect Dis* 2022; 9: ofac135. doi:10.1093/OFID/OFAC135
- [13] Griffin JB, Haddix M, Danza P, et al. SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los Angeles County, California, May 1-July 25, 2021. *MMWR Morb Mortal Wkly Rep* 2021; 70: 1170–1176. doi:10.15585/MMWR.MM7034E5

- [14] Riemersma KK, Haddock LA, Wilson NA, et al. Shedding of infectious SARS-CoV-2 despite vaccination. *PLoS Pathog* 2022; 18: e1010876. doi:10.1371/JOURNAL.PPAT.1010876
- [15] Altawalrah H, Alfouzan W, Al-Fadalah T, et al. Diagnostic Performance of Automated SARS-CoV-2 Antigen Assay in Nasal Swab during COVID-19 Vaccination Campaign. *Diagnostics* 2021; 11: 2110. doi:10.3390/DIAGNOSTICS11112110
- [16] Li J, Zhang Y, Jiang L, et al. Similar aerosol emission rates and viral loads in upper respiratory tracts for COVID-19 patients with Delta and Omicron variant infection. *Virol Sin* 2022; 37: 762–764. doi:10.1016/J.VIRS.2022.07.010
- [17] Fall A, Eldesouki RE, Sachithanandham J, et al. The displacement of the SARS-CoV-2 variant Delta with Omicron: An investigation of hospital admissions and upper respiratory viral loads. *EBioMedicine* 2022; 79: 104008. doi:10.1016/J.EBIOM.2022.104008
- [18] Hsu L, Grüne B, Buess M, et al. Covid-19 breakthrough infections and transmission risk: Real-world data analyses from Germany's largest public health department (Cologne). *Vaccines* 2021; 9: 1267. doi:10.3390/VACCINES9111267
- [19] Servellita V, Morris MK, Sotomayor-Gonzalez A, et al. Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California. *Nat Microbiol* 2022; 7: 277–288. doi:10.1038/S41564-021-01041-4
- [20] Colavita F, Meschi S, Gruber CEM, et al. Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021. *Front Med* 2022; 8: 815870. doi:10.3389/FMED.2021.815870/FULL
- [21] Miguères M, Dimeglio C, Trémeaux P, et al. Influence of the Delta Variant and Vaccination on the SARS-CoV-2 Viral Load. *Viruses* 2022; 14: 323. doi:10.3390/V14020323
- [22] Rife Magalis B, Rich S, Tagliamonte MS, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Delta Vaccine Breakthrough Transmissibility in Alachua County, Florida. *Clin Infect Dis* 2022; 75: 1618–1627. doi:10.1093/CID/CIAC197
- [23] Laura L, Dalmatin-Dragišić M, Martinović K, et al. Does pre-existing immunity determine the course of SARS-CoV-2 infection in health-care workers? Single-center experience. *Infection* 2022; 1: 1. doi:10.1007/S15010-022-01859-Y